Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

Next Previous
Trial Profile

Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors TG Therapeutics Inc

    • Most Recent Events

    • 02 Mar 2024 Results (cohort 1 (n=13; 450 mg infusion, cohort 2 n=7; 450 mg infusion) assessing the tolerability of transition from anti-CD20 therapy to ublituximab, while eliminating the 150-mg starting dose, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024.
    • 01 Mar 2024 Interim Results published in the TG Therapeutics Media Release
    • 28 Feb 2024 According to TG Therapeutics, Inc media release, company presented first data from the ENHANCE Phase 3b trial evaluating patients who switch from another CD20 antibody to BRIUMVI.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top